Mendus AB (publ) Logo

Mendus AB (publ)

IMMU.ST

(1.2)
Stock Price

8,19 SEK

-67.82% ROA

-20.01% ROE

-2.85x PER

Market Cap.

402.826.440,00 SEK

0.5% DER

0% Yield

-452.24% NPM

Mendus AB (publ) Stock Analysis

Mendus AB (publ) Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Mendus AB (publ) Fundamental Stock Analysis
# Analysis Rating
1 PBV

With a remarkably low PBV ratio (0.25x), the stock offers substantial upside potential at a bargain price.

2 DER

The stock has a minimal amount of debt (19%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

3 Graham Number

The company's Graham number suggests that its stock price is underestimated, implying that it may present a compelling investment opportunity.

4 ROE

Negative ROE (-23.36%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

5 ROA

The stock's ROA (-175.61%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

6 Revenue Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

7 Net Profit Growth

Despite the passage of five years, this company's net profit has not shown any improvement, highlighting a lack of growth and making it a less appealing investment prospect.

8 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

9 Dividend Growth

The company's dividend growth has remained flat for the past three years, offering no indication of improved returns and making it a less advantageous investment opportunity.

10 Dividend

The company's decision to withhold dividends for three years raises questions about its ability to generate consistent returns.

11 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (0) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

Mendus AB (publ) Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Mendus AB (publ) Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Mendus AB (publ) Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Mendus AB (publ) Revenue
Year Revenue Growth
2009 0
2010 0 0%
2011 5.000 100%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 16.670.000 100%
2020 0 0%
2021 6.000 100%
2022 2.995.000 99.8%
2023 0 0%
2023 28.487.000 100%
2024 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Mendus AB (publ) Research and Development Expenses
Year Research and Development Expenses Growth
2009 0
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 57.814.000 100%
2018 70.930.000 18.49%
2019 103.144.000 31.23%
2020 47.883.000 -115.41%
2021 85.796.000 44.19%
2022 87.049.000 1.44%
2023 66.548.000 -30.81%
2023 92.653.000 28.18%
2024 115.476.000 19.76%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Mendus AB (publ) General and Administrative Expenses
Year General and Administrative Expenses Growth
2009 0
2010 0 0%
2011 0 0%
2012 4.453.698 100%
2013 13.033.603 65.83%
2014 30.638.046 57.46%
2015 33.377.951 8.21%
2016 0 0%
2017 61.532.932 100%
2018 0 0%
2019 28.498.000 100%
2020 38.080.000 25.16%
2021 43.490.000 12.44%
2022 48.876.000 11.02%
2023 36.828.000 -32.71%
2023 36.776.000 -0.14%
2024 37.624.000 2.25%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Mendus AB (publ) EBITDA
Year EBITDA Growth
2009 -2.275.428
2010 -2.645.280 13.98%
2011 -2.576.301 -2.68%
2012 -6.835.289 62.31%
2013 -16.101.864 57.55%
2014 -35.933.622 55.19%
2015 -43.540.357 17.47%
2016 -73.393.470 40.68%
2017 -80.628.712 8.97%
2018 -97.846.000 17.6%
2019 -133.999.000 26.98%
2020 -86.028.000 -55.76%
2021 -128.275.000 32.93%
2022 -130.467.000 1.68%
2023 -90.676.000 -43.88%
2023 -97.846.000 7.33%
2024 -146.560.000 33.24%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Mendus AB (publ) Gross Profit
Year Gross Profit Growth
2009 0
2010 0 0%
2011 -2.696.314 100%
2012 0 0%
2013 0 0%
2014 -83.806 100%
2015 0 0%
2016 -80.794 100%
2017 -71.191 -13.49%
2018 -60.000 -18.65%
2019 15.032.000 100.4%
2020 -1.775.000 946.87%
2021 -1.845.000 3.79%
2022 -1.853.000 0.43%
2023 0 0%
2023 22.184.000 100%
2024 -6.540.000 439.2%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Mendus AB (publ) Net Profit
Year Net Profit Growth
2009 -2.287.294
2010 -2.670.303 14.34%
2011 -2.629.325 -1.56%
2012 -6.887.974 61.83%
2013 -16.175.036 57.42%
2014 -35.614.623 54.58%
2015 -43.922.885 18.92%
2016 -73.587.834 40.31%
2017 -80.337.643 8.4%
2018 -97.860.000 17.91%
2019 -135.708.000 27.89%
2020 -92.469.000 -46.76%
2021 -136.694.000 32.35%
2022 -136.991.000 0.22%
2023 -105.600.000 -29.73%
2023 -101.619.000 -3.92%
2024 -152.960.000 33.56%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Mendus AB (publ) Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2009 0
2010 0 0%
2011 0 0%
2012 0 0%
2013 -1 0%
2014 -2 100%
2015 -2 0%
2016 -49 97.92%
2017 -3 -2300%
2018 -2 -100%
2019 -2 0%
2020 -1 0%
2021 -1 0%
2022 -1 0%
2023 0 0%
2023 -4 100%
2024 -3 -33.33%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Mendus AB (publ) Free Cashflow
Year Free Cashflow Growth
2010 -2.000.064
2011 -4.902.647 59.2%
2012 -7.203.914 31.94%
2013 -9.578.916 24.79%
2014 -40.102.127 76.11%
2015 -40.228.602 0.31%
2016 -33.738.195 -19.24%
2017 -46.446.815 27.36%
2018 -104.670.000 55.63%
2019 -146.617.000 28.61%
2020 -57.090.000 -156.82%
2021 -139.394.000 59.04%
2022 -121.428.000 -14.8%
2023 -101.881.000 -19.19%
2023 -164.584.000 38.1%
2024 -22.429.000 -633.8%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Mendus AB (publ) Operating Cashflow
Year Operating Cashflow Growth
2010 -1.666.198
2011 -3.233.502 48.47%
2012 -7.146.028 54.75%
2013 -9.280.851 23%
2014 -40.102.127 76.86%
2015 -40.228.602 0.31%
2016 -33.738.195 -19.24%
2017 -46.446.815 27.36%
2018 -104.670.000 55.63%
2019 -145.808.000 28.21%
2020 -56.626.000 -157.49%
2021 -138.033.000 58.98%
2022 -109.331.000 -26.25%
2023 -101.881.000 -7.31%
2023 -162.761.000 37.4%
2024 -22.370.000 -627.59%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Mendus AB (publ) Capital Expenditure
Year Capital Expenditure Growth
2010 333.866
2011 1.669.145 80%
2012 57.886 -2783.5%
2013 298.065 80.58%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 809.000 100%
2020 464.000 -74.35%
2021 1.361.000 65.91%
2022 12.097.000 88.75%
2023 0 0%
2023 1.823.000 100%
2024 59.000 -2989.83%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Mendus AB (publ) Equity
Year Equity Growth
2009 6.590.085
2010 3.919.782 -68.12%
2011 7.626.457 48.6%
2012 24.604.113 69%
2013 100.241.320 75.46%
2014 64.626.697 -55.11%
2015 139.179.970 53.57%
2016 102.386.053 -35.94%
2017 189.556.497 45.99%
2018 406.041.000 53.32%
2019 272.781.000 -48.85%
2020 661.094.000 58.74%
2021 656.742.000 -0.66%
2022 514.439.000 -27.66%
2023 704.727.000 27%
2023 751.135.000 6.18%
2024 698.380.000 -7.55%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Mendus AB (publ) Assets
Year Assets Growth
2009 7.682.458
2010 6.246.551 -22.99%
2011 9.273.766 32.64%
2012 26.695.640 65.26%
2013 109.535.012 75.63%
2014 71.033.891 -54.2%
2015 154.239.526 53.95%
2016 121.569.942 -26.87%
2017 246.146.066 50.61%
2018 450.373.000 45.35%
2019 303.829.000 -48.23%
2020 728.661.000 58.3%
2021 720.984.000 -1.06%
2022 620.386.000 -16.22%
2023 755.952.000 17.93%
2023 807.719.000 6.41%
2024 740.961.000 -9.01%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Mendus AB (publ) Liabilities
Year Liabilities Growth
2009 1.092.373
2010 2.326.769 53.05%
2011 1.647.309 -41.25%
2012 2.091.527 21.24%
2013 9.293.692 77.5%
2014 6.407.194 -45.05%
2015 15.059.556 57.45%
2016 19.183.889 21.5%
2017 56.589.569 66.1%
2018 44.332.000 -27.65%
2019 31.048.000 -42.79%
2020 67.567.000 54.05%
2021 64.242.000 -5.18%
2022 105.947.000 39.36%
2023 51.225.000 -106.83%
2023 56.584.000 9.47%
2024 42.581.000 -32.89%

Mendus AB (publ) Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.62
Net Income per Share
-2.81
Price to Earning Ratio
-2.85x
Price To Sales Ratio
12.88x
POCF Ratio
-2.65
PFCF Ratio
-2.6
Price to Book Ratio
0.58
EV to Sales
9.48
EV Over EBITDA
-2.14
EV to Operating CashFlow
-1.95
EV to FreeCashFlow
-1.91
Earnings Yield
-0.35
FreeCashFlow Yield
-0.38
Market Cap
0,40 Bil.
Enterprise Value
0,30 Bil.
Graham Number
29.6
Graham NetNet
1.79

Income Statement Metrics

Net Income per Share
-2.81
Income Quality
1.07
ROE
-0.2
Return On Assets
-0.19
Return On Capital Employed
-0.21
Net Income per EBT
1
EBT Per Ebit
0.95
Ebit per Revenue
-4.75
Effective Tax Rate
-0.06

Margins

Sales, General, & Administrative to Revenue
1.19
Research & Developement to Revenue
3.57
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.68
Operating Profit Margin
-4.75
Pretax Profit Margin
-4.52
Net Profit Margin
-4.52

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-3.01
Free CashFlow per Share
-3.08
Capex to Operating CashFlow
-0.02
Capex to Revenue
0.1
Capex to Depreciation
0.32
Return on Invested Capital
-0.22
Return on Tangible Assets
-0.68
Days Sales Outstanding
37.72
Days Payables Outstanding
211.22
Days of Inventory on Hand
0
Receivables Turnover
9.68
Payables Turnover
1.73
Inventory Turnover
0
Capex per Share
0.06

Balance Sheet

Cash per Share
2,58
Book Value per Share
13,87
Tangible Book Value per Share
3.3
Shareholders Equity per Share
13.87
Interest Debt per Share
0.1
Debt to Equity
0.01
Debt to Assets
0
Net Debt to EBITDA
0.77
Current Ratio
8.19
Tangible Asset Value
0,17 Bil.
Net Current Asset Value
0,13 Bil.
Invested Capital
718870999
Working Capital
0,15 Bil.
Intangibles to Total Assets
0.72
Average Receivables
0,00 Bil.
Average Payables
0,01 Bil.
Average Inventory
0
Debt to Market Cap
0.01

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Mendus AB (publ) Dividends
Year Dividends Growth

Mendus AB (publ) Profile

About Mendus AB (publ)

Mendus AB (publ), a biopharmaceutical company, develops immunotherapies and relapse vaccines for the treatment of cancer. Its lead product is ilixadencel, which is in Phase II MERECA clinical trial for the treatment of kidney cancer; and Phase I/II clinical trial to treat liver cancer and gastrointestinal stromal tumors. The company's products also comprise DCP-001, which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia; and Phase I/II ALISON clinical trial for the treatment of ovarian cancers. It has a research collaboration with PCI Biotech Holding ASA for novel cancer vaccination treatment; and with Icahn School of Medicine at Mount Sinai. The company was formerly known as Immunicum AB (publ) and changed its name to Mendus AB (publ) in June 2022. Mendus AB (publ) was incorporated in 2002 and is headquartered in Stockholm, Sweden.

CEO
Dr. Erik Manting Ph.D.
Employee
28
Address
Västra Trädgårdsgatan 15
Stockholm, 111 53

Mendus AB (publ) Executives & BODs

Mendus AB (publ) Executives & BODs
# Name Age
1 Dr. Leopold Bertea Ph.D.
Chief Technology Officer
70
2 Mr. Alex Karlsson-Parra M.D., Ph.D.
Co-Founder & Chief Scientific Officer
70
3 Dr. Jeroen Rovers M.D., Ph.D.
Chief Medical Officer
70
4 Dr. Erik Manting Ph.D.
Chief Executive Officer
70
5 Ms. Lotta Ferm
Chief Financial Officer
70

Mendus AB (publ) Competitors